Senate Proposal Would Allow FDA to Fast Track Drugs for Unmet Needs
The proposal is part of ongoing talks about reauthorization of the fee system pharmaceutical companies use to fund FDA reviews. The plan proposes to allows drug companies to conduct shorter trials that are based on a measured effect of a drug — such as tumor shrinkage — instead of a clinical outcome.
Agency officials told Bloomberg that the agency already has several fast-track options in place, and 75 percent of rare-disease treatments since 2006 have been approved based on limited trials.
Related Articles on the FDA:
FDA's Dr. Jeffrey Shuren Speaks to Congress About Medical Device Approval
FDA Opens Comment Period on Device Reclassification Process
10 Recent FDA Drug and Medical Device Decisions
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
New from Becker's ASC Review
Transforming the OR Process: Instrumentation Makes a DifferenceRead Now
- 4 Tips for ASCs to Select a Business Analytics System and Streamline Collections
- Business Advisor Relationships: 4 Common Mistakes ASCs Make
- Corporate Compliance Committees: Why Healthcare Facilities Need One
- PriorityOne Launches New Corporate Identity, Moves to Bigger Office
- Online Preoperative Screening Advantages: Q&A With Ambulatory Surgical Center of Stevens Point's Becky Ziegler-Otis